[HTML][HTML] Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis
J Link, M Lundkvist Ryner, K Fink, C Hermanrud… - PLoS …, 2014 - journals.plos.org
A significant proportion of patients with multiple sclerosis who receive interferon beta (IFNβ)
therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if …
therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if …
MHC class II polymorphism is associated with a canine SLE-related disease complex
M Wilbe, P Jokinen, C Hermanrud, LJ Kennedy… - Immunogenetics, 2009 - Springer
Nova Scotia duck tolling retrievers are predisposed to a SLE-related disease complex
including immune-mediated rheumatic disease (IMRD) and steroid-responsive meningitis–arteritis …
including immune-mediated rheumatic disease (IMRD) and steroid-responsive meningitis–arteritis …
[HTML][HTML] Drug tolerant anti-drug antibody assay for infliximab treatment in clinical practice identifies positive cases earlier
N Kharlamova, C Hermanrud, N Dunn… - Frontiers in …, 2020 - frontiersin.org
A subgroup of patients treated with infliximab lose response to the treatment and one reason
for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug …
for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug …
[HTML][HTML] Treatment-and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS
TFM Andlauer, J Link, D Martin, M Ryner, C Hermanrud… - BMC medicine, 2020 - Springer
Background Upon treatment with biopharmaceuticals, the immune system may produce anti-drug
antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients …
antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients …
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
…, K Ingenhoven, L Piccoli, M Gasis, C Hermanrud… - Journal of …, 2019 - Elsevier
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared
for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with …
for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with …
Expression and purification of soluble porcine CTLA-4 in yeast Pichia pastoris
J Peraino, H Zhang, CE Hermanrud, G Li… - Protein expression and …, 2012 - Elsevier
Co-stimulation blockade can be used to modulate the immune response for induction of organ
transplantation tolerance, treatment of autoimmune disease as well as cancer treatment. …
transplantation tolerance, treatment of autoimmune disease as well as cancer treatment. …
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta
C Hermanrud, M Ryner, T Luft, PE Jensen… - Journal of …, 2016 - Elsevier
Neutralizing anti-drug antibodies (NAbs) against therapeutic interferon beta (IFNβ) in people
with multiple sclerosis (MS) are measured with cell-based bioassays. The aim of this study …
with multiple sclerosis (MS) are measured with cell-based bioassays. The aim of this study …
[HTML][HTML] Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire …
…, PEH Jensen, D Kramer, M Ryner, C Hermanrud… - Journal of …, 2022 - Elsevier
A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™)
develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We …
develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We …
Anti-drug antibodies
C Warnke, C Hermanrud, M Lundkvist… - Drugs and Therapy …, 2012 - pagepress.org
Biological pharmaceuticals are increasingly used in modern medicine and give remarkable
improvements for many different patient groups. Unfortunately, for several of these …
improvements for many different patient groups. Unfortunately, for several of these …
A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin
…, M Schenk, H Zhang, G Li, CE Hermanrud… - Journal of …, 2013 - Elsevier
Targeted cell therapies are possible through the generation of recombinant fusion proteins
that combine a toxin, such as diphtheria toxin (DT), with an antibody or other molecule that …
that combine a toxin, such as diphtheria toxin (DT), with an antibody or other molecule that …
